The IDH1 inhibitor, ivosidenib (IVO), is currently approved for relapsed/refractory IDH1-mutated MDS based on the AG120-C-001 MDS sub-study results which showed CR rates of nearly 40% and a median OS of 35.7 months [113]. Here, IDH1 is linked to myelodysplastic syndrome.